Cirrhosis is Associated with an Increased 30-Day Mortality After Venous Thromboembolism
- PMID: 26133110
- PMCID: PMC4816257
- DOI: 10.1038/ctg.2015.27
Cirrhosis is Associated with an Increased 30-Day Mortality After Venous Thromboembolism
Abstract
Objectives: Patients with cirrhosis are at increased risk of venous thromboembolism (VTE), but the impact of cirrhosis on the clinical course following VTE is unclear. In a nationwide cohort study, we examined 30-day mortality among patients with cirrhosis and VTE.
Methods: We used Danish population-based health-care databases (1994-2011) to identify patients with incident VTE, i.e., deep venous thrombosis (DVT), pulmonary embolism (PE), and portal vein thrombosis (PVT). Among these, we identified 745 patients with cirrhosis and 3647 patients without cirrhosis (matched on gender, year of birth, calendar year of VTE diagnosis and VTE type). We assessed the 30-day mortality risk among VTE patients with and without cirrhosis, and the mortality rate ratios (MRRs), using an adjusted Cox model with 95% confidence interval. We obtained information on immediate cause of death for patients who died within 30 days after VTE.
Results: The 30-day mortality risk for DVT was 7% for patients with cirrhosis and 3% for patients without cirrhosis. Corresponding PE-related mortality risks were 35% and 16%, and PVT-related mortality risks were 19% and 15%, respectively. The adjusted 30-day MRRs were 2.17 (1.24-3.79) for DVT, 1.83 (1.30-2.56) for PE, and 1.30 (0.80-2.13) for PVT. Though overall mortality was higher in patients with cirrhosis than patients without cirrhosis, the proportions of deaths due to PE were similar among patients (25% and 24%, respectively).
Conclusions: Cirrhosis is a predictor for increased short-term mortality following VTE, with PE as the most frequent cause of death.
Figures
Similar articles
-
30-year mortality after venous thromboembolism: a population-based cohort study.Circulation. 2014 Sep 2;130(10):829-36. doi: 10.1161/CIRCULATIONAHA.114.009107. Epub 2014 Jun 26. Circulation. 2014. PMID: 24970783
-
Anticoagulant therapy after venous thromboembolism and 10-year mortality.Int J Cardiol. 2016 Apr 1;208:72-8. doi: 10.1016/j.ijcard.2016.01.190. Epub 2016 Jan 18. Int J Cardiol. 2016. PMID: 26828386
-
The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism.Thromb Haemost. 2006 Mar;95(3):562-6. doi: 10.1160/TH05-10-0677. Thromb Haemost. 2006. PMID: 16525588
-
Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom.Arch Intern Med. 2007 May 14;167(9):935-43. doi: 10.1001/archinte.167.9.935. Arch Intern Med. 2007. PMID: 17502535
-
Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.Vasc Health Risk Manag. 2014 Nov 7;10:627-39. doi: 10.2147/VHRM.S50543. eCollection 2014. Vasc Health Risk Manag. 2014. PMID: 25404858 Free PMC article. Review.
Cited by
-
Hypercoagulability in End-stage Liver Disease: Review of Epidemiology, Etiology, and Management.Transplant Direct. 2018 Oct 26;4(11):e403. doi: 10.1097/TXD.0000000000000843. eCollection 2018 Nov. Transplant Direct. 2018. PMID: 30534594 Free PMC article.
-
Venous thromboembolism in in-hospital cirrhotic patients: A systematic review.Front Med (Lausanne). 2022 Nov 7;9:1027882. doi: 10.3389/fmed.2022.1027882. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36419795 Free PMC article.
-
Anticoagulation in Patients with Liver Cirrhosis: Friend or Foe?Dig Dis Sci. 2023 Jun;68(6):2237-2246. doi: 10.1007/s10620-023-07858-9. Epub 2023 Mar 24. Dig Dis Sci. 2023. PMID: 36961672 Free PMC article. Review.
-
Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to non-alcoholic steatohepatitis.Clin Transl Gastroenterol. 2018 Mar 6;9(3):140. doi: 10.1038/s41424-018-0002-y. Clin Transl Gastroenterol. 2018. PMID: 29511162 Free PMC article.
-
Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin in Cirrhotic Patients: A Systematic Review and Meta-Analysis.Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241301402. doi: 10.1177/10760296241301402. Clin Appl Thromb Hemost. 2024. PMID: 39552309 Free PMC article.
References
-
- Sogaard KK, Schmidt M, Pedersen L et al. 30-year mortality after venous thromboembolism: a population-based cohort study. Circulation 2014; 130: 829–836. - PubMed
-
- Thatipelli MR, McBane RD, Hodge DO et al. Survival and recurrence in patients with splanchnic vein thromboses. Clin Gastroenterol Hepatol 2010; 8: 200–205. - PubMed
-
- Sogaard KK, Horvath-Puho E, Gronbaek H et al. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 2009; 104: 96–101. - PubMed
-
- Wu H, Nguyen GC. Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nationwide US study. Clin Gastroenterol Hepatol 2010; 8: 800–805. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources